Article | Published:

Ophthalmology research in the UK’s National Health Service: the structure and performance of the NIHR’s Ophthalmology research portfolio

Abstract

Purpose

To report on the composition and performance of the portfolio of Ophthalmology research studies in the United Kingdom’s National Institute for Health Research (NIHR) Clinical Research Network (UK CRN).

Methods

Ophthalmology studies open to recruitment between 1 April 2010 and 31 March 2018 were classified by: sub-specialty, participant age, gender of Chief Investigator, involvement of genetic investigations, commercial/ non-commercial, interventional/observational design. Frequency distributions for each covariate and temporal variation in recruitment to time and target were analysed.

Results

Over 8 years, 137,377 participants were recruited (average of 15,457 participants/year; range: 5485–32,573) with growth by year in proportion of commercial studies and hospital participation in England (76% in 2017/18). Fourteen percent of studies had a genetic component and most studies (82%) included only adults. The majority of studies (41%) enrolled patients with retinal diseases, followed by glaucoma (17%), anterior segment and cataract (13%), and ocular inflammation (6%). Overall, 68% of non-commercial studies and 55% of commercial studies recruited within the anticipated time set by the study and also recruited to or exceeded the target number of participants.

Conclusions

High levels of clinical research activity, growth and improved performance have been observed in Ophthalmology in UK over the past 8 years. Some sub-specialties that carry substantial morbidity and a very high burden on NHS services are underrepresented and deserve more patient-centred research. Yet the NIHR and its CRN Ophthalmology National Specialty Group has enabled key steps in achieving the goal of embedding research into every day clinical care.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Additional information

Members of the NIHR Ophthalmology Specialty Group are listed before the references.

References

  1. 1.

    http://www.legislation.gov.uk/ukpga/2012/7/pdfs/ukpga_20120007_en.pdf. Accessed 1 July 2018.

  2. 2.

    http://www.crncc.nihr.ac.uk/about_us/processes/portfolio. Accessed 1 July 2018.

  3. 3.

    Bourne R, Gale R. The Ophthalmology Specialty Group and the National Institute for Health Research: the first 6 years. Eye. 2013;27:457–60.

  4. 4.

    NIHR Clinical Research Network Open Data Platform. www.odp.nihr.ac.uk. Accessed 1 July 2018.

  5. 5.

    Azuara-Blanco A, Burr J, Thomas R, Maclennan G, McPherson S. The accuracy of accredited glaucoma optometrists in the diagnosis and treatment recommendation for glaucoma. Br J Ophthalmol. 2017;91:1639–43.

  6. 6.

    https://ukctg.nihr.ac.uk. Accessed 1 July 2018.

  7. 7.

    Downing A, Morris EJ, Corrigan N, Sebag-Montefiore D, Finan PJ, Thomas JD, et al. High hospital research participation and improved colorectal cancer survival outcomes: a population-based study. Gut. 2017;66:89–96.

  8. 8.

    https://www.nihr.ac.uk/life-sciences-industry/documents/NIHR%20CRN%20Impact%20and%20Value%20FINAL%20REPORT_vSTC_160908_FOR%20EXTERNAL%20USE.pdf. Accessed 1 July 2018.

  9. 9.

    Bell J. Life sciences: industrial strategy. https://www.gov.uk/government/publications/life-sciences-industrial-strategy. Accessed 1 July 2018.

  10. 10.

    Bourne RRA, Jonas JB, Bron AM, Cicinelli MV, Das A, Flaxman SR, et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: magnitude, temporal trends and projections. Br J Ophthalmol. 2018;102:575–85.

  11. 11.

    Stapleton F, Alves M, Bunya VY, Jalbert I, Lekhanont K, Malet F, et al. TFOS DEWS II epidemiology report. Ocul Surf. 2017;15:334–65.

  12. 12.

    Xue K, Jolly JK, Barnard AR, Rudenko A, Salvetti AP, Patrício MI, et al. Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia. Nat Med. 2018;24:1507–12.

  13. 13.

    A comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in patients with open-angle glaucoma or ocular hypertension. https://clinicaltrials.gov/ct2/show/NCT02507687?term=bimatoprost&cond=Glaucoma%2C+Open-Angle&rank=1. Accessed 1 July 2018.

  14. 14.

    Edwards TL, Xue K, Meenink HCM, Beelen MJ, Naus GJL, Simunovic MP, et al. First-in-human study of the safety and viability of intraocular robotic surgery. Nat Biomed Eng. 2018;2:649–56.

  15. 15.

    De Fauw J, Ledsam J, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24:1342–50.

  16. 16.

    The Macula Society. Age-related macular degeneration: collaborating to find a cure. Appendix A. Charity, Research Council and Government funding by Health Category. UK Health Research Analysis 2014. https://www.macularsociety.org/collaborating-find-cure. Accessed 1 July 2018.

  17. 17.

    GBD 2016 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1260–1344.

  18. 18.

    National Ophthalmology Database Audit. https://www.nodaudit.org.uk. Accessed 1 July 2018.

  19. 19.

    Sivaprasad S, Prevost AT, Vasconcelos JC, Riddell A, Murphy C, Kelly J, et al. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial. Lancet. 2017;389:2193–203.

  20. 20.

    Azuara-Blanco A, Banister K, Boachie C, McMeekin P, Gray J, Burr J, et al. Automated imaging technologies for the diagnosis of glaucoma: a comparative diagnostic study for the evaluation of the diagnostic accuracy, performance as triage tests and cost-effectiveness (GATE study). Health Technol Assess. 2016;20:1–168.

  21. 21.

    Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet 2015;385:1295–304.

  22. 22.

    Sivaprasad S, Vasconcelos JC, Prevost AT, Holmes H, Hykin P, George S, et al. Clinical efficacy and safety of a light mask for prevention of dark adaptation in treating and preventing progression of early diabetic macular oedema at 24 months (CLEOPATRA): a multicentre, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol. 2018;6:382–91.

  23. 23.

    Protocol 14PRT/06545: LEAVO: a multicentre phase III double-masked randomised controlled non-inferiority trial comparing the clinical and cost effectiveness of intravitreal therapy with ranibizumab (Lucentis) vs aflibercept (Eylea) vs bevacizumab (Avastin) for macular oedema (MO) due to central retinal vein occlusion (CRVO). LEAVO Trial (2016) Lancet http://www.thelancet.com/protocol-reviews/14PRT-06545. Accessed 1 July 2018.

  24. 24.

    Azuara-Blanco A, Burr J, Ramsay C, Cooper D, Foster PJ, Friedman DS, et al. Effectiveness of early lens extraction for the treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial. Lancet. 2016;388:1389–97.

  25. 25.

    Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: two-year findings of the IVAN randomised controlled trial. Lancet. 2013;382:1258–67.

  26. 26.

    Diabetic Retinopathy Clinical Research Network. http://drcrnet.jaeb.org. Accessed 1 July 2018.

  27. 27.

    Royal College of Physicians. Research for all. https://www.rcplondon.ac.uk/projects/outputs/research-all. Accessed 1 July 2018.

  28. 28.

    The Royal College of Ophthalmologists. Workforce census 2016: a picture of the size and shape of the UK ophthalmic medical workforce. https://www.rcophth.ac.uk/2017/03/workforce-census-2016-a-picture-of-the-size-and-shape-of-the-uk-ophthalmic-medical-workforce/. Accessed 1 July 2018.

  29. 29.

    Ovseiko PV, Greenhalgh T, Adam P, Grant J, Hinrichs-Krapels S, Graham KE, et al. A global call for action to include gender in research impact assessment. Health Res Policy Syst. 2016;14:50

  30. 30.

    The Royal College of Ophthalmologists. NIHR Information for Ophthalmology Trainees. https://www.rcophth.ac.uk/professional-resources/research-hub/the-nihr-ophthalmology-clinical-research-network/useful-information-for-eye-care-professionals/nihr-information-for-ophthalmology-trainees/. Accessed 1 July 2018.

Download references

Author information

Conflict of interest

The authors declare that they have no conflict of interest.

Members of the NIHR Ophthalmology Specialty Group:

Jane Ashworth, Clare Bailey, Susan Downes, Louise Downey, Sheena George, Irene Gottlob, Christopher Hammond, Simon Harding, Jonathan Jackson, Andrew Lotery, Martin McKibbin, Luke Membrey, Pádraig J. Mulholland, Nishal Patel, George M. Saleh, Roshini Sanders, Giuliana Silvestri, Velota Sung, Deepali Varma, Marcella Votruba, Emma Worrell, Brinda Shah, Ian Nickson, Michael Beresford, Vanessa Poustie, Emma Chambers, Sarah Cooper, Cathy Yelf, Geraldine Hoad, Michele Acton, Louise Gow, Matt Broom, Christine Dickinson, Padraig Mulholland, Manjo Doug, Robert Barry

Correspondence to Rupert R. A. Bourne.

Electronic supplementary material

  1. Appendix 1

  2. Appendix 2

  3. Appendix 3

  4. Appendix 4

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5